<unk>  is a human recombinant monoclonal antibody with activity against respiratory syncytial virus, or RSV for infants. It is under development by AstraZeneca and Sanofi.<unk>  is designed to bind to the fusion protein on the surface of the RSV virus.
Nirsevimab
Atoltivimab
Regdanvimab
Odesivimab
Sotrovimab
Obiltoxaximab
Maftivimab
Bebtelovimab